New antibody drug targets Hard-to-Treat neuroendocrine cancers
NCT ID NCT05652686
First seen Jun 26, 2026 · Last updated Jul 16, 2026 · Updated 4 times
Summary
This study tests a new drug, peluntamig (PT217), in people with advanced neuroendocrine cancers like small cell lung cancer. The drug is designed to attach to two proteins (DLL3 and CD47) found on cancer cells, potentially helping the immune system attack them. The trial will first find a safe dose, then test peluntamig alone or with chemotherapy or immunotherapy in about 203 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Peluntamig (PT217), a bispecific antibody targeting DLL3 and CD47 proteins on cancer cells
- What this could lead to
- If it works, this could point toward a new treatment option for several aggressive neuroendocrine cancers that are hard to treat.
- What could go wrong
- This is an early first-in-human trial, so safety and effectiveness are not yet known. The drug may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
RECRUITINGDuarte, California, 91010, United States
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
-
Duke University Medical Center
RECRUITINGDurham, North Carolina, 27710, United States
-
Fred Hutch Cancer Center
RECRUITINGSeattle, Washington, 98109, United States
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
-
Mays Cancer Center / University of Texas, San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
-
Providence Portland Medical Center
RECRUITINGPortland, Oregon, 97213, United States
-
Sarah Cannon Research Institute University of Oklahoma
RECRUITINGOklahoma City, Oklahoma, 73104, United States
-
Sarah Cannon Research Institute at HealthONE
RECRUITINGDenver, Colorado, 80218, United States
-
Sidney Kimmel Comprehensive Cancer Center at John Hopkins
RECRUITINGBaltimore, Maryland, 21287, United States
-
USC Norris Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90033, United States
-
University of North Carolina at Chapel Hill
RECRUITINGChapel Hill, North Carolina, 27599, United States
-
Washington University School of Medicine (Siteman Cancer Center)
RECRUITINGSt Louis, Missouri, 63108, United States
-
Yale University Cancer Center
RECRUITINGNew Haven, Connecticut, 06520, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at stubborn lung cancer
- Could a hidden nerve condition be more common in lung cancer than we think?
- Can a Triple-Drug combo outsmart a rare and aggressive cancer?
- Can a gentler drug trio tame small cell lung cancer in older patients?
- Experimental combo aims to tackle Treatment-Resistant cancers
- Immunotherapy combo targets rare, aggressive lung cancer